Ignite Creation Date:
2025-12-24 @ 4:23 PM
Ignite Modification Date:
2026-02-21 @ 4:09 AM
Study NCT ID:
NCT04895566
Status:
COMPLETED
Last Update Posted:
2023-03-20
First Post:
2021-05-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
Sponsor:
SWISS BIOPHARMA MED GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-24
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-16
Completion Date Type:
ACTUAL
First Submit Date:
2021-05-17
First Submit QC Date:
None
Study First Post Date:
2021-05-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-16
Last Update Post Date:
2023-03-20
Last Update Post Date Type:
ACTUAL